NTRB - NASDAQ
Nutriband Inc.
$4.15
-0.72%Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
At a Glance
Live SnapshotNutriband Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Nutriband Inc. Cash Flow Statement
NTRB • NASDAQ
| Nutriband Inc. Cash Flow Statement | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 | Jan 2020 | Jan 2019 | Jan 2018 | Jan 2017 | Jan 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||
-10.5M | -5.5M | -4.5M | -6.2M | -2.9M | -2.7M | -3.3M | -2.7M | -151.3K | -400.0 | |
285.1K | 287.7K | 369K | 318.3K | 169.7K | 91.4K | 37K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -12.9K | 678.8K | 0.0 | 0.0 | 0.0 | 0.0 | |
1.5M | 742.7K | 732.1K | 897.8K | 2M | 252.7K | 1.8M | 0.0 | 7.8K | 0.0 | |
4M | 704.2K | 614.5K | 2.2M | 363.9K | 91.3K | 24.3K | 2.5M | 15.8K | 4.8K | |
34.1K | 223.2K | -219.3K | -541.4K | 110.2K | 713K | 400.5K | 75.1K | -4.4K | 400.0 | |
-4.6M | -3.5M | -3M | -2.8M | -297.1K | -894.5K | -1.1M | -92.9K | -147.9K | 0.0 | |
INVESTING ACTIVITIES | ||||||||||
-92K | -51.8K | -79.3K | -81.6K | (0.0) | (0.0) | -4.2K | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (67K) | (0.0) | -400K | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | -79.3K | -81.6K | 67K | 0.0 | -404.2K | 0.0 | 0.0 | 0.0 | |
-92K | -51.8K | -79.3K | -81.6K | (67K) | (0.0) | -404.2K | (92.9K) | (0.0) | (0.0) | |
FINANCING ACTIVITIES | ||||||||||
8.3M | 0.0 | -119K | 6.3M | 515.1K | 0.0 | 1.5M | 50K | 175K | 0.0 | |
8.7M | 2.1M | -17.8K | -1.6M | -161.5K | 425K | 22.4K | 7.5K | 0.0 | 100.0 | |
(0.0) | (0.0) | (0.0) | -196.6K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-149K | (0.0) | -119K | -104.5K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
69.0 | 0.0 | 296.9K | 3.1M | 18.3K | 5.3K | 461.5K | 8.3K | -100.0 | 0.0 | |
8.5M | 2.1M | 160.1K | 7.6M | 371.9K | 430.3K | 2M | 65.8K | 174.9K | 100.0 | |
CASH FLOW SUMMARY | ||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -252.0 | 394.0 | -28.0 | 47.0 | 0.0 | |
3.8M | -1.5M | -2.9M | 4.7M | 141.8K | -464.5K | 474.7K | 65.8K | 27K | 100.0 | |
492.9K | 2M | 4.9M | 152K | 10.2K | 474.7K | 0.0 | 27.1K | 100.0 | 0.0 | |
4.3M | 492.9K | 2M | 4.9M | 152K | 10.2K | 474.7K | 92.9K | 27.1K | 100.0 | |
-4.7M | -3.6M | -3.1M | -2.9M | -297.1K | -894.5K | -1.1M | -92.9K | -147.9K | 0.0 |
SEC Filings
NTRB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 07, 2026 | March 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 03, 2026 | January 24, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 30, 2025 | December 30, 2025 | 2025 | |
DEF 14A DEF 14A 2026 N/A | December 19, 2025 | January 24, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | December 11, 2025 | October 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 28, 2025 | October 28, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | September 09, 2025 | July 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 03, 2025 | February 01, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 05, 2025 | 2025 |
Related Guides
Continue your NTRB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.